What are the opening hours?

Monday 9am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm

Australasian Leukaemia & Lymphoma Group - ALLG

Home
Australia
Melbourne, VIC
Australasian Leukaemia & Lymphoma Group - ALLG

For patients, this means an improved chance of cure, and better quality of life.

Since 1973 the ALLG has been pioneering life-changing blood cancer clinical trials, delivering innovative treatment options that transform the lives of those with blood cancer. The Australasian Leukaemia & Lymphoma Group (ALLG) is the only not-for-profit, collaborative clinical research group in Australia and New Zealand dedicated to finding new ways to treat blood cancers such as leukaemia, lymphoma, myeloma and myelodysplastic syndromes. The ALLG membership includes more than 1,000 doctors, nurses, scientists and support staff across Australia and New Zealand, all of whom are looking for ways to better treat blood cancers through clinical research. By conducting national and international collaborative clinical trials at sites across Australia and New Zealand, ALLG researchers are helping to make new and more effective treatments available to people suffering from blood cancers.

11/11/2025

ALLG’s November Scientific Meeting is underway - and we have officially kicked things off with the Haematology Education Day for members..

Focused on new clinical trial research, diagnostics and treatments for Acute Myeloid Leukaemia and Acute Lymphoblastic Leukaemia, the Education Day brings together expert blood cancer researchers from across Australia & NZ to drive meaningful progress for patients.

To find out more, or to support ALLG’s leading blood cancer research, visit allg.org.au.

10/11/2025

The ALLG November Scientific Meeting starts tomorrow with our Haematology Education Day. These biannual sessions are a key benefit to ALLG members, with blood cancer experts sharing the latest research, techniques and treatments to enable our haematologists to support patients across Australia and New Zealand.

Education is a key part of ALLG’s work, helping to drive blood cancer treatments forward that support better overall survival and quality of life. To find out more about ALLG’s blood cancer research, visit allg.org.au.

06/11/2025

Graft versus host disease (GVHD) is a serious complication of a stem cell transplant - a medical procedure that replaces cancer cells in your bone marrow with healthy donor stem cells. Stem cell transplants restore the body’s ability to produce new blood cells that help your immune system fight your cancer. GVHD can impact 1 in 3 stem cell transplant patients, with new donor cells attacking the host’s cells as unfamiliar cells that need to be destroyed. GVHD affects organs such as the mouth, eyes, lungs and bowels as well skin, liver, and the gastrointestinal tract. Depending on the severity, GVHD can sometimes be fatal.

Stephanie had already beaten leukaemia once before as a teenager when she received the devastating news in July 2020 that her leukaemia was back, and she needed a stem cell transplant. She says, “While my worst fears were confirmed with my relapse, the looming threat of GVHD made everything worse. It coloured every decision I made.”

Hope came with the opportunity to participate in a clinical trial. ALLG’s BM12 CAST trial, led by Professor David Curtis, was testing a new treatment combination aimed at significantly reducing the risk of developing GVHD for patients.

Stephanie shares what being part of the trial meant to her: “The trial gave me hope – it made me feel like I was part of something bigger and like I was doing something not just for myself but for people like me in the future.” Thanks to the BM12 trial’s new treatment, Stephanie remains healthy and free of her leukaemia and GVHD.

As Australasia’s only not-for-profit blood cancer clinical trial group, ALLG and our researcher members are creating better treatments and better lives for people with blood cancers like leukaemia, lymphoma and myeloma – people just like Stephanie.

By donating to ALLG, you are supporting our leading researchers to deliver cutting edge treatment options and change the trajectory of blood cancer research in Australia and New Zealand: https://www.allg.org.au/make-a-donation/.

03/11/2025

The ALLG's November Scientific Meeting is just around the corner - 11-14 at the Park Hyatt, Melbourne. These events unite expert clinicians and our members to explore new innovative ideas and treatments in blood cancer. They are a vital to sharing knowledge of global emerging trends that have the potential to shape patient care.

ALLG is a not-for-profit organisation and relies on the support of people like you - who help drive research that has a profound impact on patients and families. To learn more and get involved, visit allg.org.au.

30/10/2025

Want to take part in a once in a lifetime event and make a difference to the future of blood cancer research? Now is your chance! ALLG is thrilled to announce that we have five charity superstar places at the 2026 Sydney Marathon, reserved specially for you – our superstar community! Follow the link - https://sm26.grassrootz.com/allg to sign up now to become a champion for all those impacted by blood cancers like leukaemia, lymphoma, and myeloma.

This is your opportunity to take part in the only World Marathon Major in the southern hemisphere and raise funds for ALLG’s vital clinical trial research into new, better treatments for blood cancers. The Sydney Marathon is now completely sold out – with charity superstar places the only way to run this amazing marathon in 2026!

Whether you’re chasing a new personal best or just looking to be part of something bigger, the Sydney Marathon 2026 is your chance to make every step count. There are only FIVE spots so hurry and sign up NOW to be part of this iconic event and become a superstar for blood cancer research in Australia and New Zealand.

Click here for your chance to be a superstar: https://sm26.grassrootz.com/allg or read more at https://tinyurl.com/53ww5ua9.

29/10/2025

ALLG is delighted to introduce our 2026 ALLG HSANZ Clinical Trials Fellow – Dr Safia Belbachir from Fiona Stanley Hospital.

The ALLG Fellowship program is vital to support the next generation of blood cancer researchers and clinical triallists to drive better treatments and outcomes for people with blood cancer. Fellows receive funding to undertake a 12-month research project into blood cancers through ALLG’s clinical trial research portfolio.

Dr Belbachir’s research project is titled, "An investigator-initiated, translational study evaluating pharmacogenomic predictors of cyclophosphamide-related toxicity and efficacy in allogeneic stem cell transplant recipients receiving post-transplant cyclophosphamide (PTCY). "

This research will investigate new ways to prevent graft-versus-host-disease (GVHD) in allogeneic stem cell transplantation by researching how genetic variations (pharmacogenomics) influence the effectiveness of key treatment post-transplant cyclophosphamide. Dr Belbachir’s research will help to guide personalised dosing and treatment selection that may lead to new, precision medicine approaches for stem cell transplant patients across Australia.

We are excited to share more about Dr Belbachir’s research throughout her 2026 Fellowship. To read more about our 2026 Fellow, visit https://tinyurl.com/y79ue84k.

If you would like to know more about the ALLG Fellowship Program and our recipients, or to make a donation to support this program, visit www.allg.org.au/support-us/our-campaigns.

27/10/2025

ALLG congratulates all our members who have had ALLG clinical trial abstracts accepted at the Blood 2025 Conference in Perth, Australia.

Our members are the driving force behind our leading clinical trials for people with leukaemia, lymphoma, myeloma and other blood cancers. Accepted research abstracts represent the most novel research in the field across Australasia and will be presented to over 1,200 haematology specialists attending Blood 2025.

This success highlights the commitment and dedication of our member researchers to ALLG’s mission of Better treatments…Better lives.

To discover more about ALLG’s research and the impact of our clinical trials for people with blood cancer, visit allg.org.au.

23/10/2025

October 25th is World MDS Day – a day to raise awareness of myelodysplastic syndromes, or MDS. This is a group of rare blood cancers that affect the bone marrow and prevent it from producing healthy blood cells.

Each year, over 16,00 people across Australia and New Zealand are diagnosed with MDS and many face limited treatment options. MDS remains a complex disease that needs more research into better, more targeted treatments.

ALLG’s MDS05 platform clinical trial is designed to offer new treatments to MDS patients that are otherwise not available to them. The innovative platform design allows new treatment arms to be added as new therapies and combinations become available.

A new arm, MDS05/D3 MESSAGE, is to open shortly in Australia for transfusion-dependent MDS. Patients with this type of MDS experience dangerously low blood counts and require regular, fortnightly blood transfusions to manage their disease. This high treatment burden greatly impacts both quality of life for people with this cancer and places a heavy load on the healthcare system.

MDS05 Chief Investigator, Associate Professor Anoop Enjeti, said, “Transfusion dependent myelodysplasia has no approved treatments currently available for Australian patients. The MDS05 MESSAGE trial’s new treatment combination aims to improve survival rates and quality of life for patients with this type of MDS by reducing the reliance on regular blood transfusions.”

At ALLG we are committed to advancing clinical trials to improve quality of life for people living with MDS and other blood cancers. With over 1,400 researcher members and 90 accredited hospital sites across Australia and New Zealand, our network is leading the way to improve how MDS is diagnosed, monitored and treated. For more information, visit allg.org.au.

20/10/2025

Our November Scientific Meeting is coming up quickly! ALLG’s biannual Scientific Meetings bring together researchers and experts to develop, discuss and generate ideas for clinical trials across all blood cancers including leukaemia, lymphoma and myeloma. ALLG clinical trials aim to deliver better treatments with better outcomes, while aiming for cure.

The ALLG Scientific Meeting is open to all ALLG Members across Australia & New Zealand. For more information about ALLG Scientific Meetings and our doctor-led clinical trial research, visit https://tinyurl.com/4u3bv4vv to read more

16/10/2025

ALLG’s vision is a world where blood cancers like leukaemia, lymphoma and myeloma can be treated effectively and even cured. Our ALLG member researchers work tirelessly to deliver leading edge clinical trials that are potentially life saving for the nearly 20,000 Australians diagnosed with blood cancer every year.

But we cannot do this without your support. ALLG receives no ongoing funding, relying on the generosity of our supporters to deliver better treatments and better lives for patients with blood cancers.

Support Research, Save Lives - please consider donating to ALLG blood cancer research today at https://www.allg.org.au/make-a-donation/.

Address

Ground Floor, 35 Elizabeth Street
Melbourne, VIC
3121

Opening Hours

Monday	9am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm

Website

https://www.allg.org.au/support-us/make-a-donation/

Alerts

Be the first to know and let us send you an email when Australasian Leukaemia & Lymphoma Group - ALLG posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Australasian Leukaemia & Lymphoma Group - ALLG:

Shortcuts

Want your practice to be the top-listed Clinic in Melbourne?

Our Story

The Australasian Leukaemia & Lymphoma Group (ALLG) is the only not-for-profit, investigator run clinical research group in Australia and New Zealand dedicated to finding new ways to treat blood cancers such as leukaemia, lymphoma, myeloma and myelodysplastic syndromes. The ALLG membership includes more than 750 doctors, nurses, scientists and professional staff across Australia and New Zealand, all of whom are looking for ways to better treat blood cancers through clinical research. By conducting national and international collaborative clinical trials at sites across Australia and New Zealand, ALLG researchers are helping to make new and more effective treatments available to people suffering from blood cancers. For patients, this means an improved chance of cure, and better quality of life.